

**KEY HIGHLIGHTS**

**May 1, 2017**

Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis

**March 7, 2017**

Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar Lines

**COMPANY BASICS**

**Headquarters**

Revance Therapeutics, Inc.  
7555 Gateway Boulevard  
P.O. Box 303  
Newark, California 94560-0303  
Phone: (510) 742-3400

**Employees:** 119 (As of March 31, 2017)

**Website:** [www.revance.com](http://www.revance.com)

Stock Symbol: RVNC

Stock Exchange: NASDAQ

Shares Outstanding: 30.3 million  
(As of April 27, 2017)

Market Cap: ~\$600 million

**Key Contacts**

Investor Relations:

Jeanie Herbert

714-325-3584

[jherbert@revance.com](mailto:jherbert@revance.com)

Burns McClellan

Ami Bavishi

212-213-0006

[abavishi@burnsmc.com](mailto:abavishi@burnsmc.com)

**Trade Media:**

Nadine Tosk

(847) 920-9858

[nadinepr@gmail.com](mailto:nadinepr@gmail.com)

**Transfer Agent**

Computershare

+1 (877) 373 6374 (US, Canada, Puerto Rico)

+1 (781) 575 3120 (non-US)

For requests by email:

[web.queries@computershare.com](mailto:web.queries@computershare.com)


# ADVANCING A LONG-LASTING, NEXT GENERATION NEUROMODULATOR

**ABOUT REVANCE THERAPEUTICS, INC.**

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology, orthopedics and neurology. Revance's science is based upon a proprietary peptide technology, which when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles, musculoskeletal conditions and muscle movement disorders. The \$3.7 billion global neurotoxin market where Revance plans to compete is estimated to grow to \$6.6 billion by 2022, and the company's drug product candidates are targeted to both infiltrate and expand the market.

The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in clinical development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis. It could be the first differentiated neuromodulator introduced in nearly 30 years and has the potential to provide increased response rates and extended duration.



The company is also developing a topically applied neurotoxin for aesthetic and therapeutic indications, DaxibotulinumtoxinA Topical Gel (RT001). Beyond botulinum toxin, Revance expects its proprietary peptide technology can be applied to a variety of other macromolecules—from over-the-counter beauty products to prescription drugs used daily to treat chronic diseases.

**ADVANCING NEUROTOXIN PIPELINE**

Botulinum Toxin is a "Pipeline within a Product"

REVANCE AESTHETICS	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
RT002 Injectable for Glabellar (Frown) Lines	[Progress bar spanning all phases]			
New RT002 Injectable Indications	[Progress bar in Pre-clinical]			
RT001 Topical	[Progress bar in Pre-clinical]			

REVANCE THERAPEUTICS	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
RT002 Injectable for Cervical Dystonia	[Progress bar spanning all phases]			
RT002 Injectable for Plantar Fasciitis	[Progress bar spanning all phases]			
New RT002 Injectable Adjacent Indications	[Progress bar in Pre-clinical]			

# REMARKABLE SCIENCE CHANGES EVERYTHING™

## REVANCE AESTHETICS

Revance is focusing on the largest segment within the facial aesthetics market, glabellar (frown) lines.



Deep facial muscles that form frown lines are approved for treatment by current injectable botulinum toxins and are estimated to represent a nearly \$1 billion global market opportunity. These marketed neurotoxins have shown duration of effect of approximately 3-4 months. In a Phase 2 trial, DaxibotulinumtoxinA for Injection (RT002) achieved a 6-month duration of effect. The company has initiated a Phase 3 clinical program using RT002 injectable for the treatment of frown lines and plans to release topline results in fourth quarter of 2017.

## REVANCE THERAPEUTICS

The therapeutic segment of the global neurotoxin market was estimated to be \$1.8 billion in 2015, larger and faster-growing than aesthetics. Revance plans to build a significant therapeutics portfolio, initially addressing cervical dystonia and plantar fasciitis.



Cervical dystonia is a very painful and debilitating neurologic disorder affecting the neck and shoulder muscles. Treatment for cervical dystonia involves regular neurological intervention. The most commonly prescribed treatment for cervical dystonia is botulinum toxin type A, which can reduce the signs and symptoms of the affliction. In December 2016, the company released positive interim results from its Phase 2 dose-escalating trial using RT002 injectable for the treatment of cervical dystonia and plans to release 24-week results, including the second and third cohorts, in the second quarter of 2017.



Plantar fasciitis, the most common cause of heel pain, is triggered by inflammation of the connective tissue in the arch of the foot. The company has initiated a Phase 2 trial using RT002 injectable to reduce the signs and symptoms of plantar fasciitis. Results are expected in the fourth quarter of 2017.

## RT001 TOPICAL

Revance plans to pursue indications for its DaxibotulinumtoxinA Topical Gel (RT001) where topical administration of botulinum toxin provides a meaningful advantage over injection. It is designed to provide treatment with no needles, no downtime, no bruising and no pain. RT001 topical is in preclinical development as a potential treatment for a number of aesthetic and therapeutic uses.

## 2016 FINANCIAL OUTLOOK (AS OF MAY 9, 2017)

The company had unaudited cash and investments of \$188.6 million at March 31, 2017. Cash burn for 2017 is expected to be in the range of \$102-\$112 million. The company expects its current cash and investments to fund operations through 2018.

## SELL-SIDE COVERAGE

FIRM	ANALYST
Aegis Capital Corp	Difei Yang
Cowen and Company	Ken Cacciatore
Piper Jaffray & Company	David Amsellem
SunTrust Robinson Humphrey, Inc.	John T. Boris
William Blair	Tim Lugo

## BOARD OF DIRECTORS

### Angus C. Russell

Chairman of the Board

### Dan Browne

Co-Founder, President & CEO

### Robert Byrnes

Experienced Medical Device & Biotechnology Executive

### Ronald Eastman

Essex Woodlands Health Ventures

### Phyllis Gardner, M.D.

Professor of Medicine, Stanford University

### Julian Gangolli

GW Pharmaceuticals Inc.

### Philip Vickers, Ph.D.

Shire plc

## MANAGEMENT TEAM

### Dan Browne

Co-Founder, President & CEO

### Lauren Silvernail

CFO & Chief Business Officer

### Abhay Joshi, Ph.D.

Chief Operating Officer

### Roman Rubio, M.D.

SVP, Clinical Development

### Mukul Agarwal

VP, Business Development

### Azita Nejad

VP, Quality and Validations

## FORWARD-LOOKING STATEMENTS

This Investor Fact Sheet contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties are risks described in the "Risk Factors" section of the Form 10-Q filed May 9, 2017. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.

"Revance Therapeutics", TransMTS®, "Remarkable Science Changes Everything", and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

© 2017 Revance Therapeutics, Inc. All rights reserved.